Brett P. Monia - 26 Jan 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Chief Executive Officer, Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Issuer symbol
IONS
Transactions as of
26 Jan 2022
Net transactions value
-$252,526
Form type
4
Filing time
28 Jan 2022, 16:58:51 UTC
Previous filing
20 Jan 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Award $0 +2,194 +2.7% $0.000000 82,424 26 Jan 2022 Direct F1
transaction IONS Common Stock Award $0 +14,004 +17% $0.000000 96,428 26 Jan 2022 Direct F2
transaction IONS Common Stock Tax liability $252,526 -8,032 -8.3% $31.44 88,396 26 Jan 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 58.06% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F2 Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 81.37% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F3 Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.